Natcocil-M 10 Tablets

babies: it does not apply to babies. lactating mothers: information regarding the use of clinidipine and metoprolol succinate tablets during breastfeeding is not available.
pregnancy: it is unsafe to use this medication in pregnancy. limited studies showed that drug effect on developing fetus.
consult your doctor before using this medicine. driving: these tablets may decrease alertness, affects vision and may cause dizziness and sleep.
do not drive if these symptoms occur. alcohol: avoid alcohol consumption while taking these tablets.
liver: clinidipine and metoprolol succinate tablets should be used with caution in patients with liver disease. you may require dosage adjustment.
seek doctor advice before using this medication. kidney: clinidipine and metoprolol succinate tablets should be used with caution in patients with kidney disease. seek doctor advice before using this medication.
.

Sleepiness Headache Ankle swelling Flushing Slow heart rate Tiredness, palpitations Nausea Edema Constipation Cold extremities.

NATCOCIL M tablets are antihypertensive agents. clinidipine is a calcium channel blocker that works by relaxing the blood vessel, while metoprolol succinate is a beta-blocker which especially works on the heart to slow down the heart rate.

If you miss a dose of NATCOCIL M, take it as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• NATCOCIL M tablets are the combination medicines that are used to treat high blood pressure • lowering blood pressure reduces the chance of future heart attacks and strokes • it may cause dizziness. get up slowly when rising from a sitting or lying position • do not stop taking the medication suddenly without talking to your doctor as it can cause a sudden increase in your blood pressure • let your doctor know if you are pregnant or planning for pregnancy.

• clinidipine+ abametapir: concurrent use leads to an increase in the serum concentration of clinidipine • clinidipine + abiraterone: concurrent use leads to an increase in the metabolism of clinidipine • clinidipine +acarbose: concurrent use leads to an increase in the risk or severity of hypoglycemia • metoprolol succinate + abcavir: concurrent use leads to a decrease in the excretion rate of abacavir • metoprolol succinate + abatacept: concurrent use leads to an increase in the metabolism of abatacept • metoprolol succinate + abiraterone: concurrent use leads to a decrease in the metabolism of metoprolol succinate.